Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics
GET POWR RATINGS... FREE!
RYTM Stock Price Chart Interactive Chart >
RYTM Price/Volume Stats
| Current price | $20.41 | 52-week high | $43.26 |
| Prev. close | $20.71 | 52-week low | $18.00 |
| Day low | $20.22 | Volume | 149,682 |
| Day high | $20.90 | Avg. volume | 415,620 |
| 50-day MA | $20.71 | Dividend yield | N/A |
| 200-day MA | $25.44 | Market Cap | 1.02B |
Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.
Latest RYTM News From Around the Web
Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceBOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET. A live audio webcast of the presentation will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to... |
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyEuropean Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger associated with confirmed loss-of-function biallelic proopiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. “People living with these rare genetic diseases experience early-on... |
Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care ConferenceBOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. ET. A live audio webcast of the fireside chat will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation. About Rhythm PharmaceuticalsRhythm is a commercial-stage bi... |
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass EstimatesRhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? |
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome -- -- Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies -- -- Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide -- BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company co... |
RYTM Price Returns
| 1-mo | -4.94% |
| 3-mo | -20.21% |
| 6-mo | -28.74% |
| 1-year | -6.55% |
| 3-year | -22.01% |
| 5-year | N/A |
| YTD | -31.35% |
| 2020 | 29.49% |
| 2019 | -14.58% |
| 2018 | -7.50% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...